Home › Funds › Ranger Investment Management, L.P. › LGND

Ranger Investment Management, L.P. position in LGND

LIGAND PHARMACEUTICALS INC · Health Care

Ranger Investment Management, L.P. reported holding 185,650 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$58.0M, representing 5.44% of its reported portfolio and ranking #1 among its reported holdings. Ranger Investment Management, L.P. has disclosed LGND holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)185.65K sh
Reported value held$57.99M
Portfolio Weight5.44%
First reportedQ1 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Ranger Investment Management, L.P.'s LGND position evolved

Ranger Investment Management, L.P. first disclosed a stake in LGND in Q1 2024 at 51,450 shares (US$3.8M). The position peaked in Q2 2026 at 257,596 shares, worth US$81.4M. Across 11 filings, Ranger Investment Management, L.P. increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 185,650 shares valued at US$58.0M — a reduction of -71,946 shares quarter over quarter.. Notable position changes include a 33% increase in Q2 2024 (shares rose 19% over the following quarter), a 131% increase in Q1 2025 (shares rose 8% over the following quarter), a 58% increase in Q2 2025 (shares rose 56% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 51.45K $3.76M New
Q2 2024 68.39K $5.76M Add
Q3 2024 83.97K $8.40M Add
Q4 2024 82.20K $8.81M Reduce
Q1 2025 190.09K $19.99M Add
Q2 2025 300.02K $34.11M Add
Q3 2025 275.34K $48.77M Reduce
Q4 2025 269.98K $51.05M Reduce
Q1 2026 267.94K $53.49M Reduce
Q2 2026 257.60K $81.42M Reduce
Q3 2026 185.65K $57.99M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LGND and 13F data

LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$139.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LGND

All LGND fund holders →

FAQ

How long has Ranger Investment Management, L.P. held LGND?

Ranger Investment Management, L.P. has disclosed LGND holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Ranger Investment Management, L.P.'s current position in LGND?

As of Q3 2026, Ranger Investment Management, L.P. holds 185.65K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $57.99M, representing 5.44% of its reported portfolio and ranking #1.

Has Ranger Investment Management, L.P. been buying or selling LGND?

In the latest 13F filing (Q3 2026), Ranger Investment Management, L.P. reduced its position in LGND. The position peaked in Q2 2026 at 257.60K shares.

Which other funds hold LGND?

Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.